Nivagen said it plans to use the proceeds for internal development and acquisition of additional generic and branded drugs to broaden its product portfolio.
The company is also exploring strategies to develop or acquire manufacturing facilities in the United States to help alleviate supply disruptions and accelerate time to market for its pipeline products.
Nivagen Pharmaceuticals is a specialty pharmaceuticals company engaged in the development and sale of difficult to formulate generic and branded prescription drugs for the North American market.
Nivagen is building a portfolio of high-quality, sustainable drug products by developing, acquiring, and in-licensing unique formulations to serve the needs of its customers.
Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology and healthcare companies.
Peak Pharma Commercial Partners establishes Resilia Pharmaceuticals and starts operations
Nephron Pharmaceuticals Corporation receives USFDA approval over Ketorolac Tromethamine Injection
Amring gains global rights to LYSTEDA
Troy Medicare Closes USD 10m Series B Led by AXA Venture Partners
Breckenridge wins final FDA approval for Pomalidomide Capsules ANDA
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Cipla reports sharp rise in demand for COVID-19 drug remdesivir in India
Sandoz ships pantoprazole sodium to Civica Rx
Russia's Pharmasyntez seeks permission to produce COVID-19 drug without patent